Rhythm Pharmaceuticals Q4 EPS $(0.70) Misses $(0.69) Estimate, Sales $24.23M Miss $25.38M Estimate
Portfolio Pulse from Benzinga Newsdesk
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported Q4 earnings with a loss of $(0.70) per share, missing the $(0.69) estimate, and sales of $24.23M, missing the $25.38M estimate. Despite these misses, the company saw a 6.67% decrease in losses and a 175.70% increase in sales compared to the same period last year.
February 22, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Rhythm Pharmaceuticals reported a Q4 EPS loss of $(0.70), missing estimates, and sales of $24.23M, also missing estimates but showed significant improvement in sales compared to last year.
Missing both EPS and sales estimates typically has a negative short-term impact on a company's stock price. However, the significant year-over-year sales growth indicates strong underlying business performance, which might mitigate some of the negative impact.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100